GlassScriptPhysician profile
Gregory A Ricketts
NPI 1770531428
$2,330.52
in general payments reported to CMS, 2019-2025
26 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $267 · 2022: $53.41 · 2023: $288 · 2024: $714 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $360.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $214.50 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $160.75 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $145.46 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $144.88 | 2019-2024 | Freestyle Libre 3 |
| Abbvie INC. | $142.14 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $140.49 | 2019-2025 | |
| Dexcom, INC. | $55.57 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $51.53 | 2019 | |
| Amarin Pharma, INC. | $48.06 | 2019-2020 | |
| Pfizer INC. | $41.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.84 | 2020-2024 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $37.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.16 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.48 | 2023 | Dificid |
| Novartis Pharmaceuticals Corporation | $30.70 | 2019-2024 | |
| Ucb, INC. | $26.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.67 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $20.43 | 2023 | Nexletol |
| Astellas Pharma US INC | $18.53 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.09 | 2024 | Voquezna |
| Shield Therapeutics INC | $15.96 | 2023 | Accrufer |
| Exact Sciences Corporation | $14.54 | 2025 | The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $14.53 | 2019 | |
| Lifescan, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ricketts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.